Dengue Virus Clinical Trial
Official title:
A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 Δ30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will test whether a vaccine developed to prevent infection with dengue virus type 2 causes a response in people's immune system and is safe.
Dengue viruses cause approximately 50 million cases of dengue fever and 1.5 million cases of
the more severe diseases dengue hemorrhagic fever (DHS) and dengue shock syndrome (DSS)
every year. There are four subtypes of the virus, and infection with one offers no
protection from infection by the others. In fact, most cases of DHS and DSS occur in people
infected by more than one subtype. In areas of the world where multiple subtypes of dengue
are common, vaccines must be developed against each of the subtypes of dengue virus. This
study will examine the safety and immune response of an investigational vaccine for
preventing dengue virus type 2.
Participation in this study will last about 6 weeks. Participants will be randomly assigned
to be injected with either the investigational study vaccine or a placebo. Participants will
have a five in six chance of receiving the vaccine. The first study visit will take place on
the vaccination day, on which participants will undergo a physical examination, blood draw,
and pregnancy test and then receive the vaccine. Participants will be given a thermometer
and temperature card and be told to record their temperatures three times per day for 16
days after vaccination. Participants will come to follow-up visits every other day for the
16 days after vaccination and then 3, 4, and 6 weeks after vaccination (Days 21, 28, and
42). Assessments completed during these visits will include a questionnaire about how the
participant is feeling, pregnancy test, review of temperature cards, blood draw, and
physical exam. Blood drawn will be analyzed to check participants' health, determine the
amount of vaccine and antibodies in the blood, test markers in white blood cells and genes,
and look for proteins that are important for fighting dengue infection.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05507450 -
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
|
Phase 2 | |
| Completed |
NCT00788151 -
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
|
Phase 2 | |
| Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
| Active, not recruiting |
NCT03141138 -
Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine
|
Phase 1 | |
| Completed |
NCT02305732 -
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
|
||
| Completed |
NCT00875524 -
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
|
Phase 2 | |
| Completed |
NCT02794181 -
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
|
||
| Completed |
NCT00842530 -
Efficacy and Safety of Dengue Vaccine in Healthy Children
|
Phase 2 | |
| Completed |
NCT00740155 -
Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
|
Phase 2 | |
| Completed |
NCT00730288 -
Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects
|
Phase 2 | |
| Completed |
NCT00880893 -
Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
|
Phase 2 | |
| Completed |
NCT01084291 -
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine
|
Phase 1 | |
| Completed |
NCT00617344 -
Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
|
Phase 2 |